Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer

Surgical Oncology

Volumn 22, Issue 2, 2013, Pages 123-131

  Kang, Chang Moo ^a   Hwang, Ho Kyoung ^a   Choi, Sung Hoon ^a   Lee, Woo Jung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Borderline resectable pancreatic cancer; Neoadjuvant treatment; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; RADIOSENSITIZING AGENT;

ADVANCED CANCER; BORDERLINE RESECTABLE PANCREAS CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; HISTOPATHOLOGY; HUMAN; MICROMETASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NOMENCLATURE; PANCREAS CANCER; PANCREAS RESECTION; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW;

CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84878819969     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2013.02.007     Document Type: Review

References (61)

1. Office. KNS. Annual report on the cause of death statistics-2007. Available from: URL: http://www.nso.go.kr (Korean).
2. M.L. Foo, L.L. Gunderson, D.M. Nagorney, D.C. McLlrath, J.A. van Heerden, and J.S. Robinow Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/-5 fluorouracil Int J Radiat Oncol Biol Phys 26 3 1993 483 489
3. H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr, and K. Ridwelski Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 3 2007 267 277
4. W.F. Regine, K.A. Winter, R.A. Abrams, H. Safran, J.P. Hoffman, and A. Konski Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 9 2008 1019 1026
5. M.W. Saif New developments in the treatment of pancreatic cancer. Highlights from the 44th ASCO Annual Meeting. Chicago, IL, USA. May 30-June 3, 2008 JOP 9 4 2008 391 397
6. M.M. Corsini, R.C. Miller, M.G. Haddock, J.H. Donohue, M.B. Farnell, and D.M. Nagorney Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005) J Clin Oncol 26 21 2008 3511 3516
7. J.M. Herman, M.J. Swartz, C.C. Hsu, J. Winter, T.M. Pawlik, and E. Sugar Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital J Clin Oncol 26 21 2008 3503 3510
8. V.K. Mehta, G. Fisher, J.A. Ford, J.C. Poen, M.A. Vierra, and H. Oberhelman Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas J Gastrointest Surg 5 1 2001 27 35
9. G.R. Varadhachary, E.P. Tamm, J.L. Abbruzzese, H.Q. Xiong, C.H. Crane, and H. Wang Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy Ann Surg Oncol 13 8 2006 1035 1046
10. J.N. Vauthey, and E. Dixon AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference Ann Surg Oncol 16 7 2009 1725 1726
11. M.H. Katz, P.W. Pisters, D.B. Evans, C.C. Sun, J.E. Lee, and J.B. Fleming Borderline resectable pancreatic cancer: the importance of this emerging stage of disease J Am Coll Surg 206 5 2008 833 846 discussion 46-8
12. C.W. Tzeng, J.B. Fleming, J.E. Lee, L. Xiao, P.W. Pisters, and J.N. Vauthey Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy Ann Surg Oncol 19 6 2012 2045 2053
13. H. Takahashi, H. Ohigashi, O. Ishikawa, K. Gotoh, T. Yamada, and S. Nagata Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer Ann Surg 255 1 2012 95 102
14. R. Le Scodan, F. Mornex, N. Girard, C. Mercier, P.J. Valette, and M. Ychou Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review Ann Oncol 20 8 2009 1387 1396
15. S. Heinrich, M. Schafer, A. Weber, T.F. Hany, U. Bhure, and B.C. Pestalozzi Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial Ann Surg 248 6 2008 1014 1022
16. D.B. Evans, G.R. Varadhachary, C.H. Crane, C.C. Sun, J.E. Lee, and P.W. Pisters Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 21 2008 3496 3502
17. G.R. Varadhachary, R.A. Wolff, C.H. Crane, C.C. Sun, J.E. Lee, and P.W. Pisters Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 21 2008 3487 3495
18. D.H. Palmer, D.D. Stocken, H. Hewitt, C.E. Markham, A.B. Hassan, and P.J. Johnson A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin Ann Surg Oncol 14 7 2007 2088 2096
19. M.H. Katz, J.B. Fleming, P. Bhosale, G. Varadhachary, J.E. Lee, and R. Wolff Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators Cancer 118 23 2012 5749 5756
20. F. Leone, M. Gatti, P. Massucco, F. Colombi, E. Sperti, and D. Campanella Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience Cancer 119 2 2012 277 284
21. S.L. Goff, and J.A. Chabot A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer Cancer J 18 6 2012 602 608
22. Y.S. Chun, B.N. Milestone, J.C. Watson, S.J. Cohen, B. Burtness, and P.F. Engstrom Defining venous involvement in borderline resectable pancreatic cancer Ann Surg Oncol 17 11 2010 2832 2838
23. Y. Zhang, J. Huang, M. Chen, and L.R. Jiao Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis Pancreatology 12 3 2012 227 233
24. J.P. Hoffman, P. O'Dwyer, P. Agarwal, H. Salazar, and N. Ahmad Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective Cancer 78 Suppl. 3 1996 592 597
25. T.R. Donahue, W.H. Isacoff, O.J. Hines, J.S. Tomlinson, J.J. Farrell, and Y.M. Bhat Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery Arch Surg 146 7 2011 836 843
26. R. White, C. Lee, M. Anscher, M. Gottfried, R. Wolff, and M. Keogan Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas Ann Surg Oncol 6 1 1999 38 45
27. A.G. Morganti, M. Massaccesi, G. La Torre, L. Caravatta, A. Piscopo, and R. Tambaro A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer Ann Surg Oncol 17 1 2010 194 205
28. A. Andriulli, V. Festa, E. Botteri, M.R. Valvano, M. Koch, and C. Bassi Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies Ann Surg Oncol 19 5 2012 1644 1662
29. S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, H. Friess, and J. Kleeff Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med 7 4 2010 e1000267
30. T.B. Brunner, G.G. Grabenbauer, T. Meyer, H. Golcher, R. Sauer, and W. Hohenberger Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO) BMC Cancer 7 2007 41
31. S. Heinrich, B. Pestalozzi, M. Lesurtel, F. Berrevoet, S. Laurent, and J.R. Delpero Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study) BMC Cancer 11 2011 346
32. F. Huguet, T. Andre, P. Hammel, P. Artru, J. Balosso, and F. Selle Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies J Clin Oncol 25 3 2007 326 331
33. S. Satoi, H. Toyokawa, H. Yanagimoto, T. Yamamoto, M. Kamata, and C. Ohe Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer J Gastrointest Surg 16 4 2012 784 792
34. C.M. Kang, Y.E. Chung, J.Y. Park, J.S. Sung, H.K. Hwang, and H.J. Choi Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer J Gastrointest Surg 16 3 2012 509 517
35. M. Sho, T. Akahori, T. Tanaka, S. Kinoshita, T. Tamamoto, and T. Nomi Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer J Hepatobiliary Pancreat Sci 20 2 2013 197 205
36. C.J. McGinn, M.M. Zalupski, I. Shureiqi, J.M. Robertson, F.E. Eckhauser, and D.C. Smith Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 19 22 2001 4202 4208
37. J.L. Lee, S.C. Kim, J.H. Kim, S.S. Lee, T.W. Kim, and H. Park do Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma Surgery 152 5 2012 851 862
38. K. Sahora, I. Kuehrer, A. Eisenhut, B. Akan, C. Koellblinger, and P. Goetzinger NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer Surgery 149 3 2011 311 320
39. J.P. Hoffman, H.S. Cooper, N.A. Young, and T.K. Pendurthi Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater J Hepatobiliary Pancreat Surg 5 3 1998 251 254
40. K.E. Todd, B. Gloor, J.S. Lane, W.H. Isacoff, and H.A. Reber Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole J Gastrointest Surg 2 2 1998 159 166
41. W.H. Isacoff, J.K. Bendetti, J.J. Barstis, A.R. Jazieh, J.S. Macdonald, and P.A. Philip Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700 J Clin Oncol 25 13 2007 1665 1669
42. S.E. Greer, J.M. Pipas, J.E. Sutton, B.I. Zaki, M. Tsapakos, and T.A. Colacchio Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma J Am Coll Surg 206 3 2008 451 457
43. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, and Y. Becouarn FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 19 2011 1817 1825
44. P.J. Hosein, J. Macintyre, C. Kawamura, J.C. Maldonado, V. Ernani, and A. Loaiza-Bonilla A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma BMC Cancer 12 2012 199
45. Zalupski MM. UMCC 2011.007: a phase II study of neoadjuvant FOLFIRINOX and FDR-gemcitabine with concurrent IMRT in patients with borderline resectable pancreatic cancer, https://www.umms.med.umich.edu/umclinicalstudies/detail-pub- study.do?show=YES&id=6574&TYPE=October 2012.
46. A pilot study of pre- and post-surgery chemotherapy with mFOLFIRINOX in localized, resectable pancreatic adenocarcinoma, http://clinicaltrialsfeeds.org/ clinical-trials/show/NCT01660711;October 2012.
47. A phase II study of preoperative systemic chemotherapy (modified FOLFIRINOX) followed by radiation therapy for patients with high risk resectable and borderline resectable adenocarcinoma of the pancreas, http:// clinicaltrials.gov/ct2/show/NCT01560949;October 2012.
48. S. Satoi, H. Yanagimoto, H. Toyokawa, T. Yamamoto, S. Hirooka, and R. Yui Long-term results of surgical resection after preoperative chemoradiation in patients with pancreatic cancer Pancreas 41 2 2012 333 335
49. A. Nakao, S. Takeda, S. Inoue, S. Nomoto, N. Kanazumi, and H. Sugimoto Indications and techniques of extended resection for pancreatic cancer World J Surg 30 6 2006 976 982 discussion 83-4
50. A. Nakao, S. Takeda, M. Sakai, T. Kaneko, S. Inoue, and H. Sugimoto Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection Pancreas 28 3 2004 289 292
51. H. Riediger, F. Makowiec, E. Fischer, U. Adam, and U.T. Hopt Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection J Gastrointest Surg 10 8 2006 1106 1115
52. M.H. Katz, J.E. Lee, P.W. Pisters, R. Skoracki, E. Tamm, and J.B. Fleming Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques J Am Coll Surg 215 2 2012 e11 e18
53. R.R. White, H.B. Xie, M.R. Gottfried, B.G. Czito, H.I. Hurwitz, and M.A. Morse Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer Ann Surg Oncol 12 3 2005 214 221
54. D.B. Evans, T.A. Rich, D.R. Byrd, K.R. Cleary, J.H. Connelly, and B. Levin Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas Arch Surg 127 11 1992 1335 1339
55. O. Ishikawa, H. Ohhigashi, T. Teshima, M. Chatani, T. Inoue, and S. Tanaka Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region J Surg Oncol 40 3 1989 143 151
56. T.M. Breslin, K.R. Hess, D.B. Harbison, M.E. Jean, K.R. Cleary, and A.P. Dackiw Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration Ann Surg Oncol 8 2 2001 123 132
57. C.P. Raut, J.F. Tseng, C.C. Sun, H. Wang, R.A. Wolff, and C.H. Crane Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma Ann Surg 246 1 2007 52 60
58. Pathologist TRCo Standards and minimum datasets for reporting cancers. Minimum dataset for the histopathological reporting of pancreatic, ampulla of Vater, and bile duct carcinoma 2002 The Royal College of Pathologists London
59. C.S. Verbeke Resection margins and R1 rates in pancreatic cancer-are we there yet? Histopathology 52 7 2008 787 796
60. M.H. Katz, N.B. Merchant, S. Brower, M. Branda, M.C. Posner, and L. William Traverso Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial Ann Surg Oncol 18 2 2011 337 344
61. H.G. Matthew, S.A. Katz, and Heidi Nelson Borderline resectable pancreatic cancer: pushing the technical limits of surgery Bull Am Coll Surg 2013 (finally assessed at -02-12) http://wordpress.facs.org/wordpress/2013/01/ resectable-panc-cancer/